Hao et al. showed that liraglutide improved hepatic steatosis and inflammation and suggested that hepatic lipid accumulation was reduced through stimulating AMPK, which downregulates the mTOR complex 1 (mTORC1)/sterol regulatory element binding protein 1 (SREBP1) signaling pathway [16]. The gene discussed is SREBF1; the disease is Hepatic steatosis.